Glymphatic dysfunction in neurodegeneration: From impaired clearance to mechanism-driven therapeutic innovation.
Level 5 - mechanism / opinion, no new human data
Narrative mechanism review without systematic search or primary human trial data.
PubMed 42430835 · doi:10.1016/j.coph.2026.102647
What was done
This narrative review synthesized mechanistic evidence on glymphatic system impairment in neurodegenerative diseases, specifically Alzheimer's disease (amyloid-β and tau), Parkinson's disease (α-synuclein), and Huntington's disease (mutant huntingtin). It examined underlying contributors—including aging, aquaporin-4 (AQP4) depolarization, vascular damage, sleep disturbances, oxidative stress, and neuroinflammation—as well as diagnostic imaging approaches and therapeutic opportunities.
What was found
The abstract reports no numerical findings or quantitative effect estimates. It summarizes that disrupted cerebrospinal fluid–interstitial fluid exchange impairs the clearance of disease-specific misfolded proteins across multiple neurodegenerative conditions, and that targeting AQP4 polarization, sleep-dependent flow, and inflammatory pathways represents potential disease-modifying approaches.
Why it matters
It highlights glymphatic clearance failure as a shared pathophysiological mechanism across diverse neurodegenerative disorders rather than an isolated feature of Alzheimer's disease. This frames perivascular fluid transport and sleep-dependent clearance as common therapeutic targets.
Limits
The abstract provides no original experimental data, sample sizes, or systematic review methodology. The causal relationship between glymphatic impairment and neurodegenerative onset versus secondary epiphenomena remains unresolved, and translational efficacy in human clinical trials has not yet been demonstrated.